Notice of Preliminary Results

RNS Number : 9220E

Ergomed plc

04 March 2020

 

 PRESS RELEASE

Notice of Preliminary Results

Guildford, UK - 4 March 2020: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its preliminary results for the year ending 31 December 2019 on 25 March 2020.

Miroslav Reljanović, Executive Chairman, Richard Barfield, Chief Financial Officer and Lewis Cameron, Chief Operating Officer will host a presentation and conference call for analysts at 9.30am GMT on the day of the results at the offices of Numis, 10 Paternoster Square, London EC4M 7LT.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Sue Stuart	[e-mail]
Matthew Neal / Olivia Manser

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com .

 

END

 

 

NORJIMMTMTBMMBM